MDT · 10-Q · 2026Q3 · Full report

Acquisition / Partnership / Divestiture

Medtronic plc · 2026-09-03 · Importance 65 · Surprise 60 · In source text

Medtronic acquired all outstanding shares of privately held Scientia Vascular on June 12, 2026, for $681 million of total consideration, including $123 million of contingent consideration. Scientia’s differentiated access products expand Medtronic’s Specialty Therapies division within Neuroscience for complex neurovascular conditions. Cash used in acquisitions increased $1.2 billion year over year during the quarter. Medtronic also identified the July 2026 SPR Therapeutics acquisition as strengthening Neuromodulation through temporary peripheral nerve stimulation technology, although transaction consideration is not provided in this section.

Key facts

• On June 12, 2026 Medtronic closed the acquisition of all outstanding shares of Scientia Vascular for $681 million of total consideration transferred, including $123 million of contingent consideration. source
• Medtronic's April 2026 acquisition of CathWorks Ltd. occurred in April 2026 and is expected to strengthen the Interventional Cardiology Therapies division. source
• During the three months ended July 31, 2026, cash used in investing activities was $1,619 million compared to $719 million in the prior year, an increase of $900 million primarily driven by an increase in acquisitions of $1.2 billion. source

Impact estimates